Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Clinical and Experimental Medicine|August 6, 2024
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabCarlo Genova, Silvia Marconi, Giovanna Chiorino, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Pageof 17